HC Wainwright Reiterates “$32.00” Price Target for CytomX Therapeutics (CTMX)
HC Wainwright set a $32.00 price target on CytomX Therapeutics (NASDAQ:CTMX) in a research report report published on Tuesday. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other research analysts have also recently weighed in on the stock. ValuEngine cut shares of CytomX Therapeutics from a buy rating to a hold rating in a research note on Monday, September 17th. BidaskClub cut shares of CytomX Therapeutics from a sell rating to a strong sell rating in a research note on Tuesday, September 11th. Finally, Zacks Investment Research cut shares of CytomX Therapeutics from a buy rating to a hold rating in a research note on Monday, August 13th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. CytomX Therapeutics presently has a consensus rating of Buy and a consensus price target of $36.86.
CTMX opened at $15.79 on Tuesday. CytomX Therapeutics has a fifty-two week low of $15.10 and a fifty-two week high of $35.00. The firm has a market cap of $831.83 million, a P/E ratio of -13.60 and a beta of 0.89.
In other CytomX Therapeutics news, insider Sean A. Mccarthy sold 13,052 shares of the business’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $21.86, for a total value of $285,316.72. Following the sale, the insider now owns 95,115 shares in the company, valued at approximately $2,079,213.90. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Debanjan Ray sold 3,000 shares of the business’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $26.05, for a total transaction of $78,150.00. Following the completion of the sale, the chief financial officer now owns 8,638 shares in the company, valued at approximately $225,019.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,052 shares of company stock worth $486,017. Corporate insiders own 8.50% of the company’s stock.
A number of hedge funds have recently made changes to their positions in CTMX. BlackRock Inc. lifted its stake in CytomX Therapeutics by 28.5% in the 2nd quarter. BlackRock Inc. now owns 3,226,401 shares of the biotechnology company’s stock worth $73,755,000 after purchasing an additional 716,096 shares in the last quarter. Aquilo Capital Management LLC purchased a new stake in CytomX Therapeutics in the 2nd quarter worth $14,853,000. Renaissance Technologies LLC lifted its stake in CytomX Therapeutics by 46.8% in the 2nd quarter. Renaissance Technologies LLC now owns 1,411,500 shares of the biotechnology company’s stock worth $32,267,000 after purchasing an additional 450,300 shares in the last quarter. Private Advisor Group LLC purchased a new stake in CytomX Therapeutics in the 2nd quarter worth $3,843,000. Finally, Point72 Asset Management L.P. purchased a new stake in CytomX Therapeutics in the 2nd quarter worth $3,616,000. Institutional investors and hedge funds own 72.03% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
See Also: What is a Call Option?
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.